BeiGene, Ltd. - American Depositary Shares (NQ:BGNE)

184.71 UNCHANGED

Last Price Updated: 4:00 PM EST, Dec 31, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BeiGene, Ltd. - American Depositary Shares

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

BeiGene's Brukinsa Prolongs Progression-Free Survival Compared To Chemo In Untreated Blood Cancer Patients ↗

July 30, 2021

BeiGene Ltd (NASDAQ: BGNE) announced positive topline results from an interim analysis of the Phase 3 SEQUOIA trial comparing Brukinsa (zanubrutinib) to...

Via Benzinga

BeiGene Announces Positive Topline Results from Phase 3 SEQUOIA Trial Comparing BRUKINSA® (Zanubrutinib) to Bendamustine Plus Rituximab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia

July 29, 2021

From BeiGene, Ltd.

Via Business Wire

Why BeiGene Stock Soared Today ↗

July 28, 2021

A regulatory filing gave a sneak peek at the company's second-quarter sales.

Via The Motley Fool

Topics Regulatory Compliance

Chinese Stock Crash ↗

July 26, 2021

For a second week in a row, we saw a big drop in stocks on Monday, while the Delta virus variant was blamed for the selloff last week, this week the cause is a big Beijing regulatory crackdown on...

Via Talk Markets

62 Biggest Movers From Yesterday ↗

July 29, 2021

Gainers Flora Growth Corp. (NASDAQ: FLGC) surged 63.1% to close at $8.27. The Miami-based cannabis producer confirmed Tuesday it has signed a non-binding letter of intent to...

Via Benzinga

Topics Cannabis

BeiGene's Brukinsa Scores Second Approval In Canada, This Time For Mantle Cell Lymphoma ↗

July 26, 2021

Health Canada has approved BeiGene Ltd (NASDAQ: BGNE) Brukinsa (zanubrutinib) for the treatment of mantle cell lymphoma (MCL) in adult patients who have received at...

Via Benzinga

BeiGene Announces Approval in Canada of BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Mantle Cell Lymphoma

July 26, 2021

From BeiGene, Ltd.

Via Business Wire

Yellow Card ↗

July 12, 2021

The price of oil fell about 1% today.

Via Talk Markets

BeiGene-Amgen's Kyprolis Gets Approval In China For Pre-Treated Multiple Myeloma Patients ↗

July 09, 2021

The China National Medical Products Administration (NMPA) has conditionally approved Kyprolis (carfilzomib) for relapsed or refractory (R/R) multiple myeloma. The...

Via Benzinga

BeiGene Announces the Approval in China of KYPROLIS® (Carfilzomib) for Injection for Adult Patients with Relapsed or Refractory Multiple Myeloma

July 09, 2021

From BeiGene, Ltd.

Via Business Wire

The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO ↗

July 09, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8) Aerpio Pharmaceuticals, Inc...

Via Benzinga

The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test ↗

July 08, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) Ambrx Biopharma Inc. (NYSE:...

Via Benzinga

Topics Product Recall

BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC)

July 07, 2021

From BeiGene, Ltd.

Via Business Wire

PureTech Health To Test LYT-200 / Tislelizumab Combo In Difficult To Treat Cancer ↗

July 07, 2021

PureTech Health plc (NASDAQ: PRTC) has announced a clinical trial and supply agreement with an affiliate of BeiGene Ltd (NASDAQ: BGNE). The partnership...

Via Benzinga

Fireworks Display ↗

July 05, 2021

The oil price rose to 76.81/bbl after the OPEC attempt to have a meeting to agree to boost production (and cut prices) was blocked.

Via Talk Markets

Week In Review: BeiGene Plans $3 Billion IPO On Shanghai STAR Market ↗

July 03, 2021

BeiGene of Beijing has been approved to stage a $3 billion IPO on the Shanghai Star Stock Exchange. It will be the first Chinese biopharma to be listed in Shanghai, Hong Kong, and the US.

Via Talk Markets

Topics Initial Public Offering

Is This Chinese Biopharma Stock Still a Buy? ↗

June 28, 2021

The pharmaceutical company had a solid first quarter and boasts a nice pipeline.

Via The Motley Fool

Week In Review: Insilico Closes $255 Million Round For AI Drug Discovery/Development ↗

June 26, 2021

Insilico Medicine, a Hong Kong company devoted to using AI to speed up drug discovery and R&D, closed a $255 million Series C round led by Warburg Pincus. The company is developing its own products and...

Via Talk Markets

Topics Artificial Intelligence

China NMPA Approves Tislelizumab in Non-Small Cell Lung Cancer and Hepatocellular Carcinoma

June 23, 2021

From BeiGene, Ltd.

Via Business Wire

A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street ↗

June 21, 2021

Pre-open movers U.S. stock futures traded higher in early pre-market trade after the Dow Jones tumbled more than 500 points in the previous session. The Chicago Fed National...

Via Benzinga

Topics Economy Stocks

5 Stocks To Watch For June 21, 2021 ↗

June 21, 2021

Some of the stocks that may grab investor focus today are: Amazon.com, Inc. (NASDAQ: AMZN) will remain in focus with the company’s two-day Prime shopping event beginning...

Via Benzinga

Week In Review: This Week's China Life Science Deals Total Over $2.5 Billion ↗

June 19, 2021

Shanghai's Zai Lab announced a four-drug immunonocology deal with MacroGenics worth over $1.4 billion. Shanghai's HutchMed (formerly Hutchison Chi-Med) is planning to raise $600 million in a Hong...

Via Talk Markets

BeiGene Announces China NMPA Approval of BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Relapsed or Refractory Waldenström’s Macroglobulinemia

June 18, 2021

From BeiGene

Via Business Wire

BeiGene Announces First Patient Dosed in Global Phase 3 Trial of Anti-TIGIT Antibody Ociperlimab in Non-Small Cell Lung Cancer

June 17, 2021

From BeiGene, Ltd.

Via Business Wire

Week In Review: Shanghai CARsgen To Raise $400 Million In Hong Kong IPO ↗

June 12, 2021

Shanghai CARsgen Therapeutics is staging an IPO on the Hong Kong Exchange that could raise $400 million to support development of the company's CAR-T portfolio. The shares are scheduled to begin...

Via Talk Markets

Topics Initial Public Offering

BeiGene Touts Initial Brukinsa Efficacy, Safety Profile For Leukemia, Compared To Imbruvica ↗

June 11, 2021

BeiGene Ltd (NASDAQ: BGNE) revealed an interim analysis of the Phase 3 ALPINE trial evaluating Brukinsa (zanubrutinib) to Johnson & Johnson’s (...

Via Benzinga

BeiGene Presents Long-Term Efficacy and Safety Results from Three Pivotal Trials of BRUKINSA® (Zanubrutinib) and Tislelizumab at EHA2021

June 11, 2021

From BeiGene, Ltd.

Via Business Wire

BeiGene Presents ALPINE Results at EHA2021 Demonstrating Both Efficacy and Safety Advantages of BRUKINSA® (Zanubrutinib) in Head-to-Head Comparison to Ibrutinib in Chronic Lymphocytic Leukemia

June 11, 2021

From BeiGene, Ltd.

Via Business Wire

BeiGene, Shoreline Biosciences Ink Development Pact For NK Cell Therapies In Cancer ↗

June 09, 2021

Shoreline Biosciences Inc and BeiGene Ltd (NASDAQ: BGNE) have announced an exclusive worldwide strategic collaboration to develop and commercialize a...

Via Benzinga

Shoreline Biosciences and BeiGene Announce Strategic Worldwide Collaboration to Develop and Commercialize Genetically Modified Natural Killer (NK) Cell Therapies

June 09, 2021

From BeiGene, Ltd.

Via Business Wire

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.